Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients

JIA Lin; WU Lei; GUO Jie; GUAN Yun

doi:10.13422/j.cnki.syfjx.20182030

您当前的位置：

首页 >

文章列表页 >

Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients

更新时间：2024-09-23

- Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 22, Pages: 148-152(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20182030
  CLC： R259
- Published：2018
- 稿件说明：
移动端阅览
JIA Lin, WU Lei, GUO Jie, et al. Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(22): 148-152.
DOI：

JIA Lin, WU Lei, GUO Jie, et al. Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(22): 148-152. DOI： 10.13422/j.cnki.syfjx.20182030.

摘要

目的：观测消风散加味对慢性持续期支气管哮喘呼出气一氧化氮浓度（fractional concentration of exhaled nitricoxide，FeNO），血浆P物质（substance P，SP）和血管活性肠肽（vasoactive intestinal peptide，VIP）含量的影响，探讨其治疗支气管哮喘的可能作用机制。方法：选取符合纳入标准的支气管哮喘患者80例，随机分为对照组和治疗组。对照组给予布地奈德福莫特罗粉吸入剂（160 μg/4.5 μg），早晚各2吸。治疗组在对照组治疗的基础之上给予消风散加味，每日1剂。两组疗程均为1个月。观察治疗前后两组患者肺功能相关指标第1秒末用力呼气量（forced expiratory volume in first second，FEV1），第1秒末用力呼气量占用力肺活量百分比（percentage of forced expiratory volume in first second and forced vital capacity，FEV1/FVC），1 s用力呼气量占预计值百分比（percentage of forced expiratory volume in first second and its predicted value，FEV1%），呼气流量峰值变异率（variety ratio of peak expiratory flow，PEF），FeNO，血浆SP，VIP水平变化，并记录两组患者不良反应。结果：治疗后两组患者肺功能指标FEV1，FEV1/FVC，FEV1%比较，治疗组均高于对照组（P<0.05）；PEF变异率比较，治疗组低于对照组（P<0.05）；治疗后治疗组患者FeNO，血浆SP水平均低于对照组（P<0.05），治疗组VIP水平高于对照组（P<0.05）；两组患者不良反应总发生率比较，治疗组低于对照组（P<0.05）。结论：消风散加味联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘与单用布地奈德福莫特罗粉吸入剂治疗相比较，可更有效改善支气管哮喘患者的肺功能，调节神经源性气道炎症水平，同时降低不良反应发生率，值得推广应用。

Abstract

Objective:To observe the effect of modified Xiaofengsan on fractional concentration of exhaled nitricoxide (FeNO)

substance P (SP) and vasoactive intestinal peptide (VIP) in plasma of patients with persistent asthma. Method:Totally 80 cases in line with the inclusion criteria were collected and randomly divided into control group and treatment group. Patients in control group were given Budesonide/formoterol(160 μg/4.5 μg)

while patients in treatment group were given modified Xiaofengsan combined with Budesonide/formoterol for 1 months. Before and after treatment

forced expiratory volume in first second(FEV1)

percentage of forced expiratory volume in first second and forced vital capacity(FEV1/FVC)

percentage of forced expiratory volume in first second and its predicted value(FEV1%)

variety ratio of peak expiratory flow

FeNO and the levels of SP and VIP in plasma were measured respectively. The adverse reactions of the two groups were recorded at the same time. Result:Compared with control group

FEV1

FEV1/FVC

FEV1%

VIP in plasma in treatment group were higher(P<0.05)

while PEF variety ratio

FeNO and the level of SP in plasma were lower (P<0.05)after treatment. Compared with control group

the incidence rate of the adverse reactions in treatment group was lower (P<0.05). Conclusion:Modified Xiaofengsan combined with Budesonide/formoterol is more effective than Budesonide/formoterol in improving pulmonary function

regulating the neurogenic airway inflammation and lowering the incidence rate of the adverse reactions. It is worth promotion and application.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guben Fangxiao decoction Regulates Expression of CGRP /ILC2 and GABA in Human Bronchial Epithelial Cells Stimulated with IL-4 Combined with IL-13

Yiqi Wenyang Huwei Decoction in Treatment of Bronchial Asthma in Rats by Regulating TGF-β₁/Smad3 Signaling Pathway

Traditional Chinese Medicine Regulates Oxidative Stress-related Signaling Pathways to Prevent and Treat Bronchial Asthma： A Review

Yiqi Wenyang Huwei Decoction Regulates PI3K/Akt/mTOR Pathway to Treat Bronchial Asthma in Rats

Effect of Shufeng Tongluo Prescription on Eotaxin and CCR3 Protein Expression and ERK Phosphorylation Level of Asthma Mice

Related Author

OU Weiying

YUAN Xuejing

JI Jianjian

SU Xiaopu

TANG Wei

YE Chao

YU Qiangqiang

SUN Peng

Related Institution

The First Clinical Medical College of Nanjing University of Chinese Medicine

Affiliated Hospital of Nanjing University of Chinese Medicine

Affiliated Hospital of Jiangxi University of Chinese Medicine

Jiangxi University of Chinese Medicine

Henan Provincial People's Hospital

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰